RecruitingNot ApplicableNCT06541990
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
HARMONY: A Psychoeducational Intervention to Reduce Psychological Distress and Improve Quality of Life for Patients With Hepatocellular Carcinoma
Sponsor
Massachusetts General Hospital
Enrollment
50 participants
Start Date
Oct 28, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age ≥18 years
- New diagnosis of HCC within the last six months
- Ability to complete study procedures English
Exclusion Criteria3
- Incidentally diagnosed with HCC after liver transplantation
- Significant uncontrolled hepatic encephalopathy, cognitive impairment, or psychiatric disorder which will interfere with study participation
- Patients near the end of life for whom hospice is recommended
Interventions
BEHAVIORALHARMONY
A psychoeducational intervention for patients with HCC
OTHEREnhanced usual care
A supportive care resource guide
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06541990
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations